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Breast cancer (BC) is a heterogenous disease, both 
genetically as well as clinically1 with need for a 
histological, molecular and functional classification system 
that can aid in devising an appropriate treatment and 
predicting clinical behavior.2 
 
“Histological classification” has been considered a 
valuable tool for classification of breast cancer subtypes 
for decades owing to its diagnostic as well as limited 
prognostic value. It characterizes different types on the 
basis of histological features like glandular/tubular 
formation, nuclear pleomorphism, and mitotic rate/10 
HPF.2  
 
Luminal A, luminal B, basal-like, normal breast like and 
ErbB2+/Her2+3,4 and recently “claudin-low”5 have been 
identified as molecular subtypes of breast cancer on 
microarray-based gene expression and hierarchical 
clustering analysis; hence the evolution of “molecular 
classification” with great potential for predicting 
therapeutic response and a better ability to predict overall 
survival as well as disease-free survival and therefore 
make prognostic predictions.3,4  
 
These gene expression patterns have been linked with 
variations in DNA copy number and mRNA. For example, 
Estrogen Receptor (ER) positive tumors (luminal A and B) 
exhibited PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 
3-Kinase Catalytic Subunit Alpha) mutations and 
ER/PR/HER2 negative presented with P53 mutations.6 
Breast cancer researchers have developed PAM50 (50-
gene signature using qRT-PCR),7 Oncotype DX (21-gene 
recurrence score) and MammaPrint (70-gene signature),8 
of which the latter two have been approved by Food and 
Drug Administration (FDA) for use in United States. 
PAM50, now named as Prosigna Breast Cancer 
Prognostic Gene Signature Assay analyzes genes in early 
stage, ER-positive BC, while Oncotype DXTM (Genomic 
Health Inc., Redwood City, CA) gives information 
regarding recurrence as well as response to 
chemotherapy in early stage, ER-positive BC. 
MammaPrintTM (Agendia, The Netherlands) gene 
signature, also done in early stage BC gives information 
regarding low-/high-risk of development of metastasis, 
with the option of not administering chemotherapy to 
patients with low risk hence sparing them the harmful side 
effects of these drugs. 
 
Cancer stem cells (CSCs), an evolving area of cancer 
research with likely focus on targeted therapy, provides 
the “functional classification” for breast cancer based on 
the hypotheses that breast cancer heterogeneity is either 
due to oncogenic transformation of single mammary stem 
cell or due to transformation of mammary stem cells at 
various levels.9 CSCs markers are used to quantify the 
percentage of these cells in a cancer patient, with high 
values indicating a poor prognosis. 
 
Understanding the histological, molecular and functional 
characteristics of a tumor will be necessary as tools for 
individualized/personalized cancer therapy in the future.2 
Ambiguities in BC classification still exist, with clinical 
routine still relying primarily on ER, PR and HER2 
immunohistochemistry as a basis for classification while 
numerous studies have been carried out on molecular 
characterization of BC.  
 
Protein expression levels in BC and their role in 
classification has not been thoroughly investigated. 
Recently mass spectrometry (MS) based proteomic 
studies have been carried out with this objective.10,11 In 
the Clinical Proteomic Tumor Analysis Consortium 
(CPTAC) study,11 novel proteomic and phosphoproteomic 
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subgroups were identified through an unsupervised tumor 
classification. The three proteomic groups identified 
included one corresponding to the luminal cluster, second 
to the basal BC cluster and the third was named as 
stromal-enriched cluster composed of tumors from 
different subtypes.6  
 
Figure 1: Evolution of breast cancer classification. 
LUMA/LUMB: luminal A/B, TN: triple negative, Ca: cancer 
 
Revere-Phase Liquid Chromatography-Mass 
Spectrometry (UHPLC – Thermo Fisher Scientific) was 
used for separation of peptides. Raw MS data was 
analyzed by MaxQuant (version 1.5.3.16)12 and 
Andomeda (an integrated peptide search engine).13 
Hierarchical clustering analysis was carried out using R 
environment (version 3.2.3) and ConsensusClusterPlus 
package.14 For information regarding protein-protein 
interaction in each group, the statistically significant up-
regulated proteins in each cluster were applied to the 
String database (http://string-db.org). This was followed 
by centrality analysis (identification of central nodes i.e. 
nodes appearing in shortest path between two other 
nodes)6 employing/with CytoNCA plug-in and 
Cytoscope.15 The Cancer Proteome Atlas (TCPA) 
provided The Cancer Genome Atlas Reverse Phase 
Protein Array (TCGA RPPA) data. 
 
The study by Yanovich and colleagues for proteomic 
classification of BC has identified a novel luminal A 
subtype with an intrinsic ER positive signature along with 
additional high expression of key signaling markers 
specific for TNBC.6 This finding suggests use of protein 
expression pattern for classification of luminal breast 
cancers, which might benefit treatment decision making. 
 
Cancer proteomics is a robust high-throughput ‘omic’ 
technology, which can be used independently and also 
complementary to other ‘omics’ like genomics, 
transcriptomics and metabolomics.  
 
Metabolomics is an “omics” science, a survey to identify 
and quantify low molecular weight metabolites that reflect 
alterations in energy metabolism. They are present 
downstream and are a reflection of the activity of genes, 
proteins and mRNA upstream. High throughput analytical 
techniques like mass spectrometry (MS) or nuclear 
magnetic resonance (NMR) are used for metabolic 
characterization using untargeted or targeted 
approaches.16 Metabolic profile can be obtained by 
analyzing the enormous raw data through specialized 
software with validation of the mass spectra obtained, 
with those available in the National Institute of Standards 
and Technology (NIST) Mass Spectral (Wiley registry) 
and Agilent Fiehn Metabolomics Retention Time Locked 
(RTL) libraries. A number of studies aimed at identifying a 
metabolomic biomarker for breast cancer have been 
carried out,16-18 however validation studies combining 
different sample types (e.g. blood, tissue, urine etc.) might 
bring an understanding of the overall metabolome of BC. 
Although cancer metabolomics has evolved over time, it is 
still lagging behind in clinical diagnostics.19  
 
The integration of multiple ‘omics’, including genomics, 
transcriptomics, proteomics and metabolomics will 
provide information regarding tumor progression, distant 
spread, and response to therapy. These experiments can 
yield high-accuracy and more robust data, exploring the 
complex heterogeneity of BC, highlighting the importance 
of an in-depth multi-level point of view in BC research. 
This will also ensure tailored healthcare involving disease 
prevention, diagnosis, and treatment in this soon-to-come 
era of personalized medicine 
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